{
    "clinical_study": {
        "@rank": "168302", 
        "arm_group": [
            {
                "arm_group_label": "Active Comparator EBI-005 5 mg/mL", 
                "arm_group_type": "Active Comparator", 
                "description": "Administered 3 times per day"
            }, 
            {
                "arm_group_label": "Placebo Comparator", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administered 3 times per day"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel,\n      Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment\n      of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC)\n      Model and Conjunctival Allergen Provocation Test (CAPT) Model. Approximately 150 subjects\n      will be enrolled and randomized in one study center in Canada for a duration of 0.33 years."
        }, 
        "brief_title": "A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide written informed consent prior to any study-related procedures.\n\n          -  Be 18 years of age or older.\n\n          -  Have at least a 2 year history of moderate to severe allergic conjunctivitis.\n\n          -  Have a positive skin prick test to ragweed within the past 12 months of Screening\n             (Visit 1A).\n\n          -  Have a score of \u2265 2 for staff-assessed ocular redness in at least one region (nasal\n             or temporal) in each eye and \u2265 2 for subject-assessed ocular itching within the\n             3.5-hour period of allergen exposure in the EEC at Visit 1B.\n\n          -  Have required more than one anti-allergy pharmaceutical treatments in the    past 2\n             years to treat ocular symptoms (including oral, topical, nasal treatments).\n\n          -  Be able to self-administer topical ophthalmic drops.\n\n          -  Avoid any topical or systemic ocular medications during the entire study  period.\n\n          -  Are willing and able to follow instructions and can be present for the required study\n             visits for the duration of the study.\n\n        Exclusion Criteria:\n\n          -  Are female and of childbearing potential and unwilling to remain abstinent through 30\n             days following the last dose of study drug or not willing to use acceptable birth\n             control methods.\n\n          -  Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept, or Ilaris).\n\n          -  Have a known contraindication or hypersensitivities to Anakinra (Kineret\u00ae) or any\n             therapeutic agent targeted to IL-1 or any component of study drug formulation.\n\n          -  Current  participation  in  another  clinical  study  involving  an  experimental\n             treatment or participation in such a study within 30 days prior to study entry.\n\n          -  Require concomitant use of TNF-blocking agents (e.g., Etanercept, Adalimumab,\n             Infliximab).\n\n          -  Have a history of glaucoma or intraocular pressure (IOP) > 25 mmHg at the Visit 1A\n             (Medical Screening) or a history of elevated IOP within the past year.\n\n          -  Have had ocular surgery including laser procedures within the past 12 months of Visit\n             1A (Medical Screening).\n\n          -  Have had contact lens wear within 4 weeks prior to Visit 1A (Medical Screening) or\n             unwilling to discontinue wear during the study period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082899", 
            "org_study_id": "EBI-005-AC-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active Comparator EBI-005 5 mg/mL", 
                "intervention_name": "Active Comparator EBI-005 5 mg/mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Comparator", 
                "intervention_name": "Placebo Comparator", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Allergic Conjunctivitis", 
            "Interleukin 1 Receptor Inhibitor", 
            "Environmental Exposure Chamber", 
            "Conjunctival Allergen Provocation Test"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mississauga", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L4W 1A2"
                }, 
                "name": "Investigation Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model", 
        "overall_contact": {
            "email": "Jennifer.Agahigian@elevenbio.com", 
            "last_name": "Jennifer Agahigian", 
            "phone": "5084797919"
        }, 
        "overall_official": {
            "affiliation": "Eleven Biotherapeutics", 
            "last_name": "Michael Goldstein, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ocular itching in EEC arm at a specific visit comparing EBI-005 vs vehicle", 
            "safety_issue": "No", 
            "time_frame": "17 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequency, severity and relationship to study medication of all Adverse Events occurring during the study.", 
                "measure": "Evaluation of Adverse Events.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 45 days"
            }, 
            {
                "description": "Number and percent of subjects who develop drug antibodies over time", 
                "measure": "Evaluation of antibodies to EBI-005.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 45 days"
            }, 
            {
                "description": "Changes in ophthalmic examinations over time.", 
                "measure": "Evaluation of ocular changes", 
                "safety_issue": "No", 
                "time_frame": "up to 45 days"
            }
        ], 
        "source": "Eleven Biotherapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eleven Biotherapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}